1 May 2024 false No description of principal activity Taxfiler 2024.6 SC476268business:PrivateLimitedCompanyLtd2024-05-012025-04-30 SC4762682024-04-30 SC4762682024-05-012025-04-30 SC476268business:AuditExemptWithAccountantsReport2024-05-012025-04-30 SC476268business:FilletedAccounts2024-05-012025-04-30 SC4762682025-04-30 SC476268business:Director12024-05-012025-04-30 SC476268business:RegisteredOffice2024-05-012025-04-30 SC4762682024-04-30 SC476268core:WithinOneYear2025-04-30 SC476268core:WithinOneYear2024-04-30 SC476268core:AfterOneYear2025-04-30 SC476268core:AfterOneYear2024-04-30 SC476268core:ShareCapitalcore:PreviouslyStatedAmount2025-04-30 SC476268core:ShareCapitalcore:PreviouslyStatedAmount2024-04-30 SC476268core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2025-04-30 SC476268core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-04-30 SC476268core:PreviouslyStatedAmount2025-04-30 SC476268core:PreviouslyStatedAmount2024-04-30 SC476268business:SmallEntities2024-05-012025-04-30 SC476268countries:Scotland2024-05-012025-04-30 SC476268core:PlantMachinery2024-05-012025-04-30 SC476268core:ComputerEquipment2024-05-012025-04-30 SC476268core:IntangibleAssetsOtherThanGoodwill2024-04-30 SC476268core:IntangibleAssetsOtherThanGoodwill2025-04-30 SC476268core:IntangibleAssetsOtherThanGoodwill2024-05-012025-04-30 SC476268core:PlantMachinery2024-04-30 SC476268core:ComputerEquipment2024-04-30 SC476268core:PlantMachinery2025-04-30 SC476268core:ComputerEquipment2025-04-30 SC476268business:OrdinaryShareClass12024-05-012025-04-30 SC476268business:OrdinaryShareClass12023-05-012024-04-30 SC4762682023-05-012024-04-30 iso4217:GBP xbrli:shares xbrli:pure
Company Registration No. SC476268 (Scotland)
The Antibody Company Limited Unaudited accounts for the year ended 30 April 2025
The Antibody Company Limited Unaudited accounts Contents
Page
- 2 -
The Antibody Company Limited Company Information for the year ended 30 April 2025
Director
E Wagner
Company Number
SC476268 (Scotland)
Registered Office
10 Church Avenue Newmains Lanarkshire ML2 9BH
Accountants
Assenti & Noble Ltd 18 Mosshead Road Bearsden Glasgow G61 3HN
- 3 -
The Antibody Company Limited Statement of financial position as at 30 April 2025
2025 
2024 
Notes
£ 
£ 
Fixed assets
Intangible assets
6,074 
7,592 
Tangible assets
15,676 
28,622 
21,750 
36,214 
Current assets
Inventories
33,750 
45,000 
Debtors
147,800 
33,066 
Cash at bank and in hand
35,016 
77,874 
216,566 
155,940 
Creditors: amounts falling due within one year
(207,414)
(147,723)
Net current assets
9,152 
8,217 
Total assets less current liabilities
30,902 
44,431 
Creditors: amounts falling due after more than one year
(23,240)
(37,876)
Net assets
7,662 
6,555 
Capital and reserves
Called up share capital
1,000 
1,000 
Profit and loss account
6,662 
5,555 
Shareholders' funds
7,662 
6,555 
For the year ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 7 January 2026 and were signed on its behalf by
E Wagner Director Company Registration No. SC476268
- 4 -
The Antibody Company Limited Notes to the Accounts for the year ended 30 April 2025
1
Statutory information
The Antibody Company Limited is a private company, limited by shares, registered in Scotland, registration number SC476268. The registered office is 10 Church Avenue, Newmains, Lanarkshire, ML2 9BH.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention.
Presentation currency
The accounts are presented in £ sterling.
Intangible fixed assets
Intangible fixed assets comprising purchased licences are capitalised and written off on a straight line basis over a 10 year period. Provision is made for any impairment in value.
Tangible fixed assets policy
Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Plant & machinery
between 2 & 5 years straight line
Computer equipment
4 years straight line
4
Intangible fixed assets
Other 
£ 
Cost
At 1 May 2024
15,183 
At 30 April 2025
15,183 
Amortisation
At 1 May 2024
7,591 
Charge for the year
1,518 
At 30 April 2025
9,109 
Net book value
At 30 April 2025
6,074 
At 30 April 2024
7,592 
- 5 -
The Antibody Company Limited Notes to the Accounts for the year ended 30 April 2025
5
Tangible fixed assets
Plant & machinery 
Computer equipment 
Total 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At 1 May 2024
161,563 
25,020 
186,583 
Additions
- 
1,166 
1,166 
At 30 April 2025
161,563 
26,186 
187,749 
Depreciation
At 1 May 2024
135,784 
22,177 
157,961 
Charge for the year
12,811 
1,301 
14,112 
At 30 April 2025
148,595 
23,478 
172,073 
Net book value
At 30 April 2025
12,968 
2,708 
15,676 
At 30 April 2024
25,779 
2,843 
28,622 
6
Debtors
2025 
2024 
£ 
£ 
Amounts falling due within one year
Trade debtors
117,811 
25,549 
Accrued income and prepayments
11,800 
2,480 
Other debtors
18,189 
5,037 
147,800 
33,066 
7
Creditors: amounts falling due within one year
2025 
2024 
£ 
£ 
Bank loans and overdrafts
5,833 
5,833 
VAT
19,134 
5,469 
Obligations under finance leases and hire purchase contracts
8,809 
8,809 
Trade creditors
34,009 
10,344 
Taxes and social security
1,017 
800 
Other creditors
37,738 
48,844 
Loans from directors
10,024 
24 
Accruals
90,850 
49,600 
Deferred income
- 
18,000 
207,414 
147,723 
8
Creditors: amounts falling due after more than one year
2025 
2024 
£ 
£ 
Bank loans
15,900 
21,727 
Obligations under finance leases and hire purchase contracts
7,340 
16,149 
23,240 
37,876 
- 6 -
The Antibody Company Limited Notes to the Accounts for the year ended 30 April 2025
9
Share capital
2025 
2024 
£ 
£ 
Allotted, called up and fully paid:
1,000 Ordinary shares of £1 each
1,000 
1,000 
10
Average number of employees
During the year the average number of employees was 4 (2024: 5).
- 7 -